Comparative molecular analysis of early and late cancer cachexia-induced muscle wasting in mouse models

Sun,Rulin; Zhang,Santao; Lu,Xing; Hu,Wenjun; Lou,Ning; Zhao,Yan; Zhou,Jia; Zhang,Xiaoping; Yang,Hongmei

doi:10.3892/or.2016.5165

Comparative molecular analysis of early and late cancer cachexia-induced muscle wasting in mouse models

Authors:
- Rulin Sun
- Santao Zhang
- Xing Lu
- Wenjun Hu
- Ning Lou
- Yan Zhao
- Jia Zhou
- Xiaoping Zhang
- Hongmei Yang
View Affiliations

Affiliations: Department of Pathogenic Biology, School of Basic Medicine, Tonji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: October 12, 2016 https://doi.org/10.3892/or.2016.5165
Pages: 3291-3302

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer-induced muscle wasting, which commonly occurs in cancer cachexia, is characterized by impaired quality of life and poor patient survival. To identify an appropriate treatment, research on the mechanism underlying muscle wasting is essential. Thus far, studies on muscle wasting using cancer cachectic models have generally focused on early cancer cachexia (ECC), before severe body weight loss occurs. In the present study, we established models of ECC and late cancer cachexia (LCC) and compared different stages of cancer cachexia using two cancer cachectic mouse models induced by colon-26 (C26) adenocarcinoma or Lewis lung carcinoma (LLC). In each model, tumor-bearing (TB) and control (CN) mice were injected with cancer cells and PBS, respectively. The TB and CN mice, which were euthanized on the 24th day or the 36th day after injection, were defined as the ECC and ECC-CN mice or the LCC and LCC-CN mice. In addition, the tissues were harvested and analyzed. We found that both the ECC and LCC mice developed cancer cachexia. The amounts of muscle loss differed between the ECC and LCC mice. Moreover, the expression of some molecules was altered in the muscles from the LCC mice but not in those from the ECC mice compared with their CN mice. In conclusion, the molecules with altered expression in the muscles from the ECC and LCC mice were not exactly the same. These findings may provide some clues for therapy which could prevent the muscle wasting in cancer cachexia from progression to the late stage.

View Figures

View References

1	Argilés JM, Busquets S, Stemmler B and López-Soriano FJ: Cancer cachexia: Understanding the molecular basis. Nat Rev Cancer. 14:754–762. 2014. View Article : Google Scholar : PubMed/NCBI
2	Li B, Wan L, Li Y, Yu Q, Chen P, Gan R, Yang Q, Han Y and Guo C: Baicalin, a component of Scutellaria baicalensis, alleviates anorexia and inhibits skeletal muscle atrophy in experimental cancer cachexia. Tumour Biol. 35:12415–12425. 2014. View Article : Google Scholar : PubMed/NCBI
3	Talbert EE, Metzger GA, He WA and Guttridge DC: Modeling human cancer cachexia in colon 26 tumor-bearing adult mice. J Cachexia Sarcopenia Muscle. 5:321–328. 2014. View Article : Google Scholar : PubMed/NCBI
4	Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, et al: IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 119:285–298. 2004. View Article : Google Scholar : PubMed/NCBI
5	Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S and Guttridge DC: Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest. 114:370–378. 2004. View Article : Google Scholar : PubMed/NCBI
6	Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, Koniaris LG and Zimmers TA: JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab. 303:E410–E421. 2012. View Article : Google Scholar : PubMed/NCBI
7	Ham DJ, Murphy KT, Chee A, Lynch GS and Koopman R: Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. Clin Nutr. 33:448–458. 2014. View Article : Google Scholar : PubMed/NCBI
8	Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG and Zimmers TA: STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. 6:e225382011. View Article : Google Scholar : PubMed/NCBI
9	Murphy KT, Chee A, Trieu J, Naim T and Lynch GS: Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia. Dis Model Mech. 5:533–545. 2012. View Article : Google Scholar : PubMed/NCBI
10	Zhang G, Jin B and Li YP: C/EBPβ mediates tumour-induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wasting. EMBO J. 30:4323–4335. 2011. View Article : Google Scholar : PubMed/NCBI
11	Busquets S, Toledo M, Orpí M, Massa D, Porta M, Capdevila E, Padilla N, Frailis V, López-Soriano FJ, Han HQ, et al: Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachexia Sarcopenia Muscle. 3:37–43. 2012. View Article : Google Scholar : PubMed/NCBI
12	Ruas JL, White JP, Rao RR, Kleiner S, Brannan KT, Harrison BC, Greene NP, Wu J, Estall JL, Irving BA, et al: A PGC-1α isoform induced by resistance training regulates skeletal muscle hypertrophy. Cell. 151:1319–1331. 2012. View Article : Google Scholar : PubMed/NCBI
13	Reed SA, Sandesara PB, Senf SM and Judge AR: Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. FASEB J. 26:987–1000. 2012. View Article : Google Scholar : PubMed/NCBI
14	Puppa MJ, Gao S, Narsale AA and Carson JA: Skeletal muscle glycoprotein 130s role in Lewis lung carcinoma-induced cachexia. FASEB J. 28:998–1009. 2014. View Article : Google Scholar : PubMed/NCBI
15	He SS, Wu QJ, Gong CY, Luo ST, Zhang S, Li M, Lu L, Wei YQ and Yang L: Enhanced efficacy of combination therapy with adeno-associated virus-delivered pigment epithelium-derived factor and cisplatin in a mouse model of Lewis lung carcinoma. Mol Med Rep. 9:2069–2076. 2014.PubMed/NCBI
16	Wang H, Lai YJ, Chan YL, Li TL and Wu CJ: Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia. Cancer Lett. 305:40–49. 2011. View Article : Google Scholar : PubMed/NCBI
17	Fearon KC, Glass DJ and Guttridge DC: Cancer cachexia: Mediators, signaling, and metabolic pathways. Cell Metab. 16:153–166. 2012. View Article : Google Scholar : PubMed/NCBI
18	Johns N, Stephens NA and Fearon KC: Muscle wasting in cancer. Int J Biochem Cell Biol. 45:2215–2229. 2013. View Article : Google Scholar : PubMed/NCBI
19	McPherron AC, Lawler AM and Lee SJ: Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 387:83–90. 1997. View Article : Google Scholar : PubMed/NCBI
20	Padrão AI, Oliveira P, Vitorino R, Colaço B, Pires MJ, Márquez M, Castellanos E, Neuparth MJ, Teixeira C, Costa C, et al: Bladder cancer-induced skeletal muscle wasting: Disclosing the role of mitochondria plasticity. Int J Biochem Cell Biol. 45:1399–1409. 2013. View Article : Google Scholar : PubMed/NCBI
21	Padrão AI, Moreira-Gonçalves D, Oliveira PA, Teixeira C, Faustino-Rocha AI, Helguero L, Vitorino R, Santos LL, Amado F, Duarte JA, et al: Endurance training prevents TWEAK but not myostatin-mediated cardiac remodelling in cancer cachexia. Arch Biochem Biophys. 567:13–21. 2015. View Article : Google Scholar : PubMed/NCBI
22	Gallot YS, Durieux AC, Castells J, Desgeorges MM, Vernus B, Plantureux L, Rémond D, Jahnke VE, Lefai E, Dardevet D, et al: Myostatin gene inactivation prevents skeletal muscle wasting in cancer. Cancer Res. 74:7344–7356. 2014. View Article : Google Scholar : PubMed/NCBI
23	Han HQ, Zhou X, Mitch WE and Goldberg AL: Myostatin/activin pathway antagonism: Molecular basis and therapeutic potential. Int J Biochem Cell Biol. 45:2333–2347. 2013. View Article : Google Scholar : PubMed/NCBI
24	Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, et al: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142:531–543. 2010. View Article : Google Scholar : PubMed/NCBI
25	Lokireddy S, Wijesoma IW, Bonala S, Wei M, Sze SK, McFarlane C, Kambadur R and Sharma M: Myostatin is a novel tumoral factor that induces cancer cachexia. Biochem J. 446:23–36. 2012. View Article : Google Scholar : PubMed/NCBI
26	Ramaswamy S, Nakamura N, Sansal I, Bergeron L and Sellers WR: A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell. 2:81–91. 2002. View Article : Google Scholar : PubMed/NCBI
27	Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH and Goldberg AL: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 117:399–412. 2004. View Article : Google Scholar : PubMed/NCBI
28	Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, et al: Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 294:1704–1708. 2001. View Article : Google Scholar : PubMed/NCBI
29	Gomes MD, Lecker SH, Jagoe RT, Navon A and Goldberg AL: Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA. 98:14440–14445. 2001. View Article : Google Scholar : PubMed/NCBI
30	Cohen S, Nathan JA and Goldberg AL: Muscle wasting in disease: Molecular mechanisms and promising therapies. Nat Rev Drug Discov. 14:58–74. 2015. View Article : Google Scholar : PubMed/NCBI
31	Wang DT, Yang YJ, Huang RH, Zhang ZH and Lin X: Myostatin activates the ubiquitin-proteasome and autophagy-lysosome systems contributing to muscle wasting in chronic kidney disease. Oxid Med Cell Longev. 2015:6849652015. View Article : Google Scholar : PubMed/NCBI
32	Attaix D, Ventadour S, Codran A, Béchet D, Taillandier D and Combaret L: The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem. 41:173–186. 2005. View Article : Google Scholar : PubMed/NCBI
33	Taillandier D, Combaret L, Pouch MN, Samuels SE, Béchet D and Attaix D: The role of ubiquitin-proteasome-dependent proteolysis in the remodelling of skeletal muscle. Proc Nutr Soc. 63:357–361. 2004. View Article : Google Scholar : PubMed/NCBI
34	Lokireddy S, Wijesoma IW, Sze SK, McFarlane C, Kambadur R and Sharma M: Identification of atrogin-1-targeted proteins during the myostatin-induced skeletal muscle wasting. Am J Physiol Cell Physiol. 303:C512–C529. 2012. View Article : Google Scholar : PubMed/NCBI
35	Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, Goldberg AL and Spiegelman BM: PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA. 103:16260–16265. 2006. View Article : Google Scholar : PubMed/NCBI
36	Esterbauer H, Oberkofler H, Krempler F and Patsch W: Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression. Genomics. 62:98–102. 1999. View Article : Google Scholar : PubMed/NCBI
37	Puigserver P: Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha. Int J Obes. 29:(Suppl 1). S5–S9. 2005. View Article : Google Scholar
38	Brault JJ, Jespersen JG and Goldberg AL: Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J Biol Chem. 285:19460–19471. 2010. View Article : Google Scholar : PubMed/NCBI
39	Cannavino J, Brocca L, Sandri M, Bottinelli R and Pellegrino MA: PGC1-α over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice. J Physiol. 592:4575–4589. 2014. View Article : Google Scholar : PubMed/NCBI
40	Wenz T, Rossi SG, Rotundo RL, Spiegelman BM and Moraes CT: Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci USA. 106:20405–20410. 2009. View Article : Google Scholar : PubMed/NCBI
41	Ramji DP and Foka P: CCAAT/enhancer-binding proteins: Structure, function and regulation. Biochem J. 365:561–575. 2002. View Article : Google Scholar : PubMed/NCBI
42	Allen DL, Bandstra ER, Harrison BC, Thorng S, Stodieck LS, Kostenuik PJ, Morony S, Lacey DL, Hammond TG, Leinwand LL, et al: Effects of spaceflight on murine skeletal muscle gene expression. J Appl Physiol (1985). 106:582–595. 2009. View Article : Google Scholar : PubMed/NCBI
43	Penner G, Gang G, Sun X, Wray C and Hasselgren PO: C/EBP DNA-binding activity is upregulated by a glucocorticoid-dependent mechanism in septic muscle. Am J Physiol Regul Integr Comp Physiol. 282:R439–R444. 2002. View Article : Google Scholar : PubMed/NCBI
44	Zhang G and Li YP: p38β MAPK upregulates atrogin1/MAFbx by specific phosphorylation of C/EBPβ. Skelet Muscle. 2:202012. View Article : Google Scholar : PubMed/NCBI
45	McKinsey TA, Zhang CL and Olson EN: Control of muscle development by dueling HATs and HDACs. Curr Opin Genet Dev. 11:497–504. 2001. View Article : Google Scholar : PubMed/NCBI
46	Alamdari N, Aversa Z, Castillero E and Hasselgren PO: Acetylation and deacetylation - novel factors in muscle wasting. Metabolism. 62:1–11. 2013. View Article : Google Scholar : PubMed/NCBI
47	Yang H, Wei W, Menconi M and Hasselgren PO: Dexamethasone-induced protein degradation in cultured myotubes is p300/HAT dependent. Am J Physiol Regul Integr Comp Physiol. 292:R337–R334. 2007. View Article : Google Scholar : PubMed/NCBI
48	Demos-Davies KM, Ferguson BS, Cavasin MA, Mahaffey JH, Williams SM, Spiltoir JI, Schuetze KB, Horn TR, Chen B, Ferrara C, et al: HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling. Am J Physiol Heart Circ Physiol. 307:H252–H258. 2014. View Article : Google Scholar : PubMed/NCBI
49	Beharry AW, Sandesara PB, Roberts BM, Ferreira LF, Senf SM and Judge AR: HDAC1 activates FoxO and is both sufficient and required for skeletal muscle atrophy. J Cell Sci. 127:1441–1453. 2014. View Article : Google Scholar : PubMed/NCBI
50	Greco S, De Simone M, Colussi C, Zaccagnini G, Fasanaro P, Pescatori M, Cardani R, Perbellini R, Isaia E, Sale P, et al: Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. FASEB J. 23:3335–3346. 2009. View Article : Google Scholar : PubMed/NCBI
51	Guess MG, Barthel KK, Harrison BC and Leinwand LA: miR-30 family microRNAs regulate myogenic differentiation and provide negative feedback on the microRNA pathway. PLoS One. 10:e01182292015. View Article : Google Scholar : PubMed/NCBI
52	Cavallo F, Calogero RA and Forni G: Are oncoantigens suitable targets for anti-tumour therapy? Nat Rev Cancer. 7:707–713. 2007. View Article : Google Scholar : PubMed/NCBI
53	Das SK, Eder S, Schauer S, Diwoky C, Temmel H, Guertl B, Gorkiewicz G, Tamilarasan KP, Kumari P, Trauner M, et al: Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 333:233–238. 2011. View Article : Google Scholar : PubMed/NCBI
54	Kliewer KL, Ke JY, Tian M, Cole RM, Andridge RR and Belury MA: Adipose tissue lipolysis and energy metabolism in early cancer cachexia in mice. Cancer Biol Ther. 2014.PubMed/NCBI
55	Minetti GC, Colussi C, Adami R, Serra C, Mozzetta C, Parente V, Fortuni S, Straino S, Sampaolesi M, Di Padova M, et al: Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med. 12:1147–1150. 2006. View Article : Google Scholar : PubMed/NCBI
56	Moresi V, Williams AH, Meadows E, Flynn JM, Potthoff MJ, McAnally J, Shelton JM, Backs J, Klein WH, Richardson JA, et al: Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell. 143:35–45. 2010. View Article : Google Scholar : PubMed/NCBI